ORIGINAL ARTICLE

Malignant phyllodes tumors of the breast: A single

institution experience

Liew Kah Weng, MB BCH BAO, Siti Zubaidah Sharif, MS, Doreen Lee, MS

Breast and Endocrine Department, Hospital Queen Elizabeth 2, Kota Kinabalu, Sabah

ABSTRACT
Background: Malignant phyllodes tumors of the breast are
to malignant phyllodes.4 These aggressive tumors accounts

uncommon fibroepithelial breast tumors with diverse

for less than 0.5% of all breast malignancies.1 The

biological behavior. Our study aim is to share our

recommended treatment of phyllodes tumor remains surgery.

experience in treating patients with malignant phyllodes

Mastectomy and breast conserving surgery can be carried out

presenting to our center.

with a margin of at least 1cm to treat this tumor effectively.1,5
However the local recurrence rate following breast conserving

Patients and methods: A total of 11 cases of malignant

surgery are 8% for benign phyllodes tumors and 21-36% for

phyllodes were retrospectively reviewed between Nov 2014

borderline and malignant tumors.5,6 Lymph node

and Oct 2017. Results: The median age was 45 years old (31-
involvement is rarely found in phyllodes tumor. So the role of

61 years). The median pathological tumor size was 10.5cm

axillary dissection has been a debate among breast surgeons.

(2-28cm). 6 patients (55%) were premenopausal. 7 patients

Axillary node sampling could be considered for high risk

(64%) were treated eventually with mastectomy and 4 (36%)

patients. 7

were treated with breast conserving surgery. 4 (36%)

patients had Axillary Clearance done while axillary sampling
Postop adjuvant radiotherapy for malignant phyllodes

was done in 2 patient. The remainder 5 (45%) required

tumors has also been recommended as it has shown to be

axillary clearance at a later op. 6 (55%) patients received

effective in decreasing recurrence rates after breast

postoperative radiotherapy. After a median follow up period

conserving surgery.6 Subsequently, malignant phyllodes

of 11 months (range 4-33 months), 8 developed local

usually presents as a huge tumor involving more than 1

recurrence. The overall 2 year survival rate was 18%.

quadrant so achieving wide margins of > 1cm can be
challenging even if a total mastectomy was performed. Some

Conclusion: Malignant Phyllodes tumors are rare tumors

studies have indicated that RT will help to reduce recurrence

that occur in fairly young women, when compared with the

in these patients.6

adenocarcinoma of the breast. They tend to grow to reach

large with absence of nodal metastasis. Ultimately surgery
The role of adjuvant chemotherapy is highly debatable. Most

is the mainstay of management but with postoperative

patients present with huge masses and ulcerating tumors

radiotherapy it can decrease the local recurrence rates in

with distant metastasis. These patients are usually not fit for

certain presentations however recurrence rate is high and

chemotherapy and a through discussion should be conducted

overall survival rates are poor.

with the breast surgeon, oncologist and the patient to weight
the risks and benefits of the treatment. Some of the tumors

KEY WORDS:
may have positive hormone receptors in their epithelial
component however hormonal therapy has been shown not
Breast, phyllodes, surgery, radiotherapy, follow up, survival rate to be effective.8

INTRODUCTION
So the mainstay of treatment is with surgery and with or
without adjuvant radiotherapy. The survival rate for
Malignant phyllodes tumors of the breast are rare malignant phyllodes tumors has be reported to me 60-80% at
fibroepithelial breast tumors that acts aggressively and 5 years.9 Patients with metastatic disease do less well with 13-
usually presents as a huge tumor of the breast. They can be 40% 5 year survival rate. 9 The most frequent metastasis
classified as benign, borderline or malignant1,2 according to usually involves the lung. The mean survival is 30 months
the degree of stromal cellular atypia, mitotic activity, after the development of metastases.10
infiltrative versus circumscribed tumor margins and presence

AIM OF THE STUDY

or absence of stromal overgrowth.3 The benign form may act
similar to fibroadenomas while the malignant form tends to
grow rapidly and may present with distant metastasis. This is a retrospective study to look at the presentation,
Unfortunately, even with wide excision margins, these pathological features, prognostic factors and treatment
tumors have a very high local recurrence rate.2 outcomes for patient who presented with malignant
phyllodes tumors of the breast to Breast and Endocrine
From a histopathological viewpoint, the stromal elements are Department, Hospital Queen Elizabeth 2, Kota Kinabalu,
the key components in differentiation of phyllodes tumor Sabah (HQE2).
from giant fibroadenoma or distinguishing it from a benign

This article was accepted: 2 August 2018

Corresponding Author: Kah Weng Liew
Email: weng55@hotmail.com

Med J Malaysia Vol 73 No 5 October 2018 297

Original Article

Table I: Demographic data of patients presenting with malignant phyllodes

PATIENTS AND METHODS benign core biopsy results while 4 had suspicious lesion noted
The medical records of HQE2 were accessed and all diagnoses from core biopsy. Initially, 4 patients (36%) were planned for
made of malignant phyllodes tumors of the breast were breast conserving surgery , unfortunately the surgical
extracted. HQE2 is the only tertiary hospital with breast and margins were all involved except for 1 patient. Secondary
endocrine surgical unit with 2 experienced breast and surgery which was a mastectomy with axillary clearance was
endocrine surgeons providing care for the whole of Sabah. A performed in the other 3 patients. Definitive surgery of
search of the records from Nov 2014 to October 2017 revealed mastectomy and axillary clearance was carried out in 7
a total of 11 interesting cases of malignant phyllodes tumors. patients (64%). Axillary node sampling was performed for 2
The clinical and pathological data were studied patients which resulted in reactive lymph nodes free from
retrospectively from the medical and pathological records. tumor infiltration. 7 patients had axillary clearance done
and only one patient had positive lymph nodes. 9 patients

RESULTS
presented with huge tumors involving more than 1 quadrant.
The median pathological tumor size was 10.5cm (2-28cm). 6
The demographic data of the 11 patients are summarized in patients had adjuvant RT (5 following mastectomy and 1
Table I. All 11 patients were female with a median age of 45 after BCS). The dose of post mastectomy RT was 50Gy/25# in
years old (31-61 years) at time of diagnosis. These patients two patients while one had additional boost 10Gy/5#.
were followed up closely in the clinic with a median of 11 Following breast conserving surgery, the RT dose was
months (range 4-33 months). 6 patients (55%) were 50Gy/25# in two patients and 60Gy/30# for the one patient.
premenopausal. All of the patients presented with a breast Unfortunately, 4 patients post adjuvant RT had local
mass with a median duration of symptoms of 24 months (2- reoccurrence.
360months). Only 1 patient had a positive family history of
breast malignancy. 4 patients had mammography done In our sample group only 2 patients had distant metastasis.
reported as recurrent phyllodes tumor, BIRADS 3, BIRADS 4 One had lung nodules and the other had lung and liver
and BIRADS 5. Ultrasonography of the breast was employed lesions. 8 patients had local reoccurrence. 3 patients were
in 2 patients which shows suspicion of breast malignancy treated with mastectomy after the initial breast conserving
and benign breast lesion. Core biopsy revealing malignant surgery. Surgical Margins were involved in 3 patients with 2
phyllodes tumor was only found in 3 patients. 2 patients had patients requiring a later mastectomy. Throughout the follow

298 Med J Malaysia Vol 73 No 5 October 2018

 Malignant phyllodes tumors of the breast: A single institution experience

Fig. 1: Patient with huge phyllodes tumor. Fig. 2: Patient with huge phyllodes tumor.

Fig. 3: Patient with ulcerating and bleeding phyllodes tumor. Fig. 4: Patient with huge phyllodes tumor.

up, four patients were still alive at the end of October 2017. Phyllodes tumors tend to present as a huge breast mass with
Unfortunately, the overall 2 year survival rate from time of abnormal mammographic findings. Our study found that
diagnosis was 18%. the median tumor size is 10cm with one case presenting as
ulcerating and bleeding breast mass. Other literature has

DISCUSSION
shown the median size to be 4-7cm.1

Malignant phyllodes tumors of the breast are rare rumors For phyloddes tumor, it is usually reported as a smooth,
with an average annual incidence of 2.1 per million women.3 polylobulated mass resembling fibroadenoma in
We studied 11 female patients diagnosed with this disease mammography. However in our setting, mammography is
presenting to our centre. We found that malignant phyllodes seldom performed as patient usually present very late with a
tumors of the breast tend to present at a younger age very huge mass and locally advanced disease deeming them
population compared to breast cancer. The median age in unsuitable for mammography. In our study only 4 patients
our study was 45 years compared to 50 years for breast cancer had a mammography done. The huge mass at presentation
in Malaysia11 and comparable to 42-45 years worldwide.3 and rapid growth will raise suspicion for a phyllodes tumor
rather than a fibroadenoma.2 Core biopsy was done in most
of our cases as that is the standard of care before surgical
intervention was carried out.

Med J Malaysia Vol 73 No 5 October 2018 299

Original Article

In our study only 2 core biopsy results reported as malignant CONCLUSION

phyllodes tumor of the breast while one had borderline Malignant phyllodes tumors of the breast are rare tumors
phyllodes tumour reported. Another 2 core biopsy revealed that occur in relatively young woman when compared to
necrotic breast tissue with inflammatory cells and atypical breast cancer. They have a tendency to grow into very large
spindle cell lesion of uncertain malignant potential and 1 breast mass with the absence of axillary nodal metastasis.
revealed benign fibrous stroma. Subsequently all mastectomy Total mastectomy or breast conserving surgery is the gold
and breast conserving surgery specimen yield malignant standard of treatment for these cases and postop adjuvant
phyllodes tumors of the breast. radiotherapy has proven to decrease local recurrence rate.
From our data, although the 2 year survival rate was very low
We also found that, 3 patients had positive surgical margins we should not be discouraged. In our setting, most patients
with 2 undergoing breast conserving surgery. This could be present very late with very huge breast mass and distant
explained by the infiltrative nature of the tumor. Ultimately, metastases. To combat this we must spend more time on
10 patients required mastectomy as their initial surgery or understanding this breast disease and patient education and
after their breast conserving surgery to treat this tumor. Only awareness is very important so that we can treat this disease
one patient had a wide local excision and adjuvant effectively.
radiotherapy after not requiring mastectomy but this could

REFERENCES
be explained by the small tumor size of 2.5cm.

Although axillary lymph node involvement is rarely 1. Reinfuss M, Mitus´ J, Duda K, Stelmach A, Rys´ J, Smolak K. The treatment
and prognosis of patients with phyllodes tumor of the breast: an analysis
described in phyllodes tumor12, 2 patients had axillary node
of 170 cases. Cancer 1996; 77: 910-16.
sampling done and 7 patients had axillary clearance done. 2. Calhoun KE, Lawton TJ, Kim JN, Lehman CD, Anderson BO. Phyllodes
Nodal metastasis was only detected in one patient. Literature tumors. In: Harris J, Lippman ME, Osborne CK, Morrow M, editors.
has shown that axillary dissection was not recommended in Diseases of the breast. Philadelphia: Lippincott Williams &Wilkins; 2010.
p. 781-92.
these cases but it was carried out in our center due to the huge 3. Bernstein L, Deapen D, Ross RK. The descriptive epidemiology of
mass on presentation and the likelihood of defaulting follow malignant cystosarcoma phyllodes tumors of the breast. Cancer 1993; 71:
up as most patients are from rural areas.12 3020-4.
4. Norris HJ, Taylor HB. Relationship of histologic features to behavior of
cystosarcoma phyllodes. Analysis of ninety-four cases. Cancer 1967; 20:
Studies have shown that adjuvant radiotherapy can lower 2090-9.
the rates of local reoccurrence in malignant phyllodes 5. Barth Jr RJ, Wells WA, Mitchell SE, Cole BF. A prospective, multi-
tumors.13 A total of 6 patients in our study underwent institutional study of adjuvant radiotherapy after resection of malignant
phyllodes tumors. Ann Surg Oncol 2009; 16: 2288-94.
adjuvant radiotherapy however only 2 patients did not 6. Barth Jr RJ. Histologic features predict local recurrence after breast
experience local reoccurrence after radiotherapy. conserving therapy of phyllodes tumors. Breast Cancer Res Treat 1999; 57:
291-5.
7. Ramakant P, Chakravarthy S, Cherian JA, Abraham DT, Paul MJ.
The local recurrence rate in our study was 72% (8 out of 11
Challenges in management of phyllodes tumors of the breast: a
patients) compared to the recurrence rates reported in retrospective analysis of 150 patients. Indian J Cancer. 2013; 50(4): 345-8.
literature (8-19%).13 3 patients required total mastectomy post 8. Telli ML, Horst KC, Guardino AE, Dirbas FM, Carlson RW. Phyllodes
BCS to treat the local recurrence. Only 2 patients had distant tumors of the breast: natural history, diagnosis, and treatment. J Natl
Compr Canc Netw 2007; 5: 324-30.
metastasis in our study. One had lung nodules and the other 9. Chaney AW, Pollack A, McNeese MD, Zagars GK, Pisters PW, Pollock RE,
had lung and liver lesions. et al. Primary treatment of cystosarcoma phyllodes of the breast. Cancer
2000; 89: 1502–11.
10. Kessinger A, Foley JF, Lemon HM, Miller DM. Metastatic cystosarcoma
In our center, all of the patient who was treated for
phyllodes: a case report and review of the literature. J Surg Oncol 1972; 4:
malignant phyllodes tumor of the breast were followed up at 131-4.
3 monthly intervals. The median follow up was 11 months 11. Hisham AN, Yip CH. Overview of breast cancer in Malaysian women: a
with a range of 4-33 months. This follows the same breast problem with late diagnosis. Asian J Surg 2004 Apr; 27(2): 130-3.
12. Macdonald OK, Lee CM, Tward JD, Chappel CD, Gaffney DK. Malignant
cancer follow up protocol defined by NCCN guidelines.14 phyllodes tumor of the female breast: association of primary therapy with
cause-specific survival from the Surveillance, Epidemiology, and End
Results (SEER) program. Cancer 2006; 107: 2127–33.
13. Pezner RD, Schultheiss TE, Paz IB. Malignant phyllodes tumor of the
breast: local control rates with surgery alone. Int J Radiat Oncol Biol Phys
2008; 71: 710-3.
14. NCCN guidelines of treatment of cancer by site: breast cancer. Ver. 1.2016.
http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

300 Med J Malaysia Vol 73 No 5 October 2018